Mendus is focused on advancing cancer treatment by leveraging the immune system to combat tumor recurrence, which is a leading cause of cancer-related deaths. The company develops innovative therapies that aim to build active immunity against residual cancer cells, thereby enhancing long-term survival while maintaining patients' health and quality of life. Their approach includes the use of dendritic cell biology to create off-the-shelf immunotherapies, such as vididencel and ilixadencel, which are designed to stimulate robust immune responses against tumors. Vididencel utilizes irradiated leukemic-derived dendritic cells to provoke broad immune reactions, while ilixadencel involves administering pro-inflammatory dendritic cells directly into tumors to incite localized immune responses.

Mendus is actively engaged in clinical trials for various cancer types, including Acute Myeloid Leukemia (AML), ovarian cancer, and soft tissue sarcomas. Their lead program, vididencel, is being explored as a maintenance therapy for AML patients with measurable residual disease, showing promising results in early trials. Additionally, ilixadencel has demonstrated clinical efficacy in treating hard-to-manage solid tumors and is being evaluated in combination with other cancer therapies. The company is committed to addressing unmet needs in cancer care by developing novel cell therapy products that enhance the body’s immune response to fight cancer effectively.

Sweden

Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST.

Mendus

Company Details